Abstract
The role of inflammation in asthma has been the main theme of various guidelines on its treatment and the emphasis of the National Asthma Education Program (NAEP). There are several treatment options when selecting anti-inflammatory agents for managing asthma patients. Although inhaled corticosteroids are associated with considerably fewer side effects than oral corticosteroids, and currently are the anti-inflammatory medication of choice, they nevertheless have certain side effects. In the usual doses, they have been shown to be safe and well tolerated. However, with higher doses, they can produce adverse effects such as oral candidiasis, dysphonia, osteoporosis, possible growth retardation and even ocular effects, such as glaucoma and cataract formation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Suggested Reading
Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157: 1381–1389.
Grossman J, Smith LJ. Long-term safety and efficacy of zafirlukast in the treatment of asthma: Interim results of an open-label extension trial. Ann Allergy Asthma Immunol 1999; 82: 361–369.
Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–1451.
Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. JAllergy Clin Immunol 1996; 98: 859–871.
Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998; 102: 935–942.
National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997.
Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030–1035.
Spector SL. Leukotriene activity modulation in asthma. Drugs 1997; 54: 369–384.
Spector SL, Smith LJ, Glass M, “Accolate” Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI-204,219, a leukotriene D receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618–623.
Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177–183.
Virchow J, Hassall SM, Summerton L. Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids. J Investig Med 1997; 45: 286A.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Spector, S.L. (2000). Antileukotriene Agents in the Management of Asthma. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-007-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-59259-007-0_20
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4477-4
Online ISBN: 978-1-59259-007-0
eBook Packages: Springer Book Archive